Metabolic and vascular effects of antidiabetic drugs Machado HA et al. CLINICS 2012;67(7):711-717 Table 2 - Glucose, glycated hemoglobin, insulin, total and fractional cholesterol, triglycerides and catecholamine levels. Glucose (mmol/L) HbA1 (%) Insulin (pmol/L) Total cholesterol (mmol/L) HDL cholesterol (mmol/L) LDL cholesterol (mmol/L) VLDL cholesterol (mmol/L) Triglyceride (mmol/L) Norepinephrine (nmol/dL) Epinephrine (nmol/dL) t-PA activity (IU/mL) Pre-treatment 15.1¡5.12 10.8¡2.3 59.5¡22.9 5.41¡1.29 0.99¡0.21 3.45¡1.16 0.92¡0.54 2.01¡1.19 1481.0¡986.4 104.7¡176.8 1.1¡0.5 Metformin Group Glimepiride Group 7.10¡1.34 8.2¡1.4 55.9¡29.4 5.05¡0.93 1.01¡0.18 3.32¡0.80 0.66¡0.31 1.38¡0.67 913.3¡497.5 26.1¡72 0.7¡0.3 8.3¡1.7 7.8¡1.3 79.6¡25.8 5.23¡1.09 0.95¡0.22 3.64¡0.90 0.70¡0.25 1.46¡0.60 958.7¡414.7 16.3¡49.6 0.8¡0.3 p-value a0.00011 b0.037 a0.009 b0.001 c0.009 Ns Ns Ns d0.007 d0.023 d0.042 Ns d0.024 a(pre-treatment vs. metformin); b(pre-treatment vs. glimepiride); c(metformin vs. glimepiride); d(pre. vs. post-treatment). Values are expressed as means ¡ SDs. Figure 1 - 12-h metabolic profiles of glucose, triglyceride, insulin, proinsulin and glucagon levels. Mean levels are indicated. 714